Skip to main content
Premium Trial:

Request an Annual Quote

Hologic Posts 7 Percent Q1 Revenue Growth

NEW YORK (GenomeWeb) – Hologic reported after the close of the market Wednesday that its first quarter revenues increased 7 percent year over year , driven by the international blood screening market and the domestic molecular diagnostics market.

The Bedford, Mass.-based firm reported total revenues of $652.8 million for the three months ended Dec. 27, 2014, up from $612.5 million for Q1 2014 and in line with its announcement earlier this month of preliminary revenues of $653 million.

Hologic reported molecular diagnostics revenues of $119.1 million, up from $112.8 million in Q1 2014, which the firm credited to strong sales growth in the domestic market. Blood screening revenues were up 14 percent year over year to $64.9 million from $51.3 million, driven by the firm's partnership with Grifols, which signed an agreement to perform blood screening services for the Japanese Red Cross Society.

The firm said that it will ramp up R&D for its diagnostics pipeline and expects new products for the Procleix Panther System over the next few years, including viral load testing.

Sales of its diagnostics products totaled $304.1 million in the quarter, up 6 percent year over year, while breast health sales were up 7 percent at $242 million, GYN surgical sales were also up 7 percent at $84.4 million, and skeletal health sales increased nearly 5 percent to $22.3 million.

US revenues grew 6 percent in the quarter to $483.3 million from $457.6 million year over year, and international revenues were up 9 percent to $169.5 million from $154.9 million, largely based on Grifols' deal with the Japanese Red Cross.

Hologic posted net income of $29.2 million, or $.10 per share, as opposed to a $5.3 million loss, or $.02 per share, in Q1 2014. On a non-GAAP basis, its EPS was $.39 versus $.34 for Q1 2014, beating analysts' consensus estimate of $.36.

The firm reported cash and cash equivalents of $544 million and restricted cash of $5.1 million as of the end of the first quarter. Its financial guidance projected revenues of $640 million to $650 million for Q2 2015, or $.38 to $.39 per share.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.